Kohlberg inks deal to acquire CRO Worldwide Clinical Trials

2023-08-08
FierceBiotech
并购高管变更
Kohlberg inks deal to acquire CRO Worldwide Clinical Trials
Preview
来源: FierceBiotech
CRO Worldwide Clinical Trials has signed an agreement to be acquired by Kohlberg & Co. for an undisclosed price.
Kohlberg & Co. has reached a definitive agreement to acquire North Carolina-based CRO Worldwide Clinical Trials.
Although the financial terms of the deal weren’t disclosed, the sale is expected to be completed by the end of the year pending regulatory approval.
Worldwide, which is an affiliate of TJC, boasts more than 3,200 employees in about 60 countries, according to an Aug. 7 press release. The CRO is focused on cardiovascular, metabolic, neuroscience, oncology and rare diseases.
When the acquisition is completed, Matt Jennings, operating partner at Kohlberg, will assume the title of chairman of the board for Worldwide.
Jefferies acted as financial advisor to Worldwide and Kirkland & Ellis served as legal counsel to TJC and Worldwide. Centerview Partners was the financial advisor and the law firm of Paul, Weiss, Rifkind, Wharton & Garrison represented Kohlberg.
In recent months, Worldwide also inked partnerships with Every Cure and Cybin.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
-
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。